

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Charles Wieland on 05/04/11.

The application has been amended as follows:

Rejoinder of withdrawn claims

Claims 1-2, 4-10, and 14 are allowable. The restriction requirement between the claims of Group I and Group III, as set forth in the Office action mailed on 06/24/10, has been reconsidered in view of the allowability of claims to the elected invention pursuant to MPEP § 821.04(a). **The restriction requirement is hereby withdrawn as to any claim that requires all the limitations of an allowable claim.** Claims 11-13 and 17, directed to CMV resistant plant/seed are no longer withdrawn from consideration because the claim(s) requires all the limitations of an allowable claim.

In view of the above noted withdrawal of the restriction requirement, applicant is advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application.

Once a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

In The Claims:

Claim 2 (Currently amended). The [An] isolated nucleic acid of Claim 1 further comprising a primer for the detection of a CMV-resistant plant, which comprises the [a consecutive nucleotide selected from a] nucleotide sequence set forth in SEQ ID NOs: 23, 24, 25, 26, 27, or [to] 28.

At claims 11-13 and 17, in line 2, "a nucleotide sequence" is replaced with the ---- the nucleotide sequence---.

Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MEDINA A. IBRAHIM whose telephone number is (571)272-0797. The examiner can normally be reached on M-TH 8:00 am to 5:30 PM, and every other Friday from 8:00 AM to 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached on 571-272-0975. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1638

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MAI
5/4/2011

/MEDINA A IBRAHIM/
Primary Examiner, Art Unit 1638